Rational design of a protein that binds integrin α(v)β(3) outside the ligand binding site

Ravi Chakra Turaga, Georgia State University
Lu Yin, Georgia State University
Jenny J Yang, Georgia State University
Hsiauwei Lee, Georgia State University
Ivaylo Ivanov, Georgia State University
Chunli Yan, Georgia State University
Hua Yang, Emory University
Hans Grossniklaus, Emory University
Siming Wang, Georgia State University
Cheng Ma, Georgia State University

Only first 10 authors above; see publication for full author list.

**Journal Title:** Nature Communications  
**Volume:** Volume 7  
**Publisher:** Nature Publishing Group | 2016-05-01, Pages 11675-11675  
**Type of Work:** Article | Final Publisher PDF  
**Publisher DOI:** 10.1038/ncomms11675  
**Permanent URL:** https://pid.emory.edu/ark:/25593/rnkqq

Final published version: [http://dx.doi.org/10.1038/ncomms11675](http://dx.doi.org/10.1038/ncomms11675)

**Copyright information:**
© 2016, Rights Managed by Nature Publishing Group
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).

Accessed August 10, 2019 7:45 AM EDT
Rational design of a protein that binds integrin $\alpha_v\beta_3$ outside the ligand binding site

Ravi Chakra Turaga1,*, Lu Yin1,*, Jenny J. Yang2, Hsiauwei Lee2, Ivaylo Ivanov2, Chunli Yan2, Hua Yang3, Hans E. Grossniklaus3, Siming Wang2, Cheng Ma2, Li Sun4 & Zhi-Ren Liu1

Integrin $\alpha_v\beta_3$ expression is altered in various diseases and has been proposed as a drug target. Here we use a rational design approach to develop a therapeutic protein, which we call ProAgio, that binds to integrin $\alpha_v\beta_3$ outside the classical ligand-binding site. We show ProAgio induces apoptosis of integrin $\alpha_v\beta_3$-expressing cells by recruiting and activating caspase 8 to the cytoplasmic domain of integrin $\alpha_v\beta_3$. ProAgio also has anti-angiogenic activity and strongly inhibits growth of tumour xenografts, but does not affect the established vasculature. Toxicity analyses demonstrate that ProAgio is not toxic to mice. Our study reports a new integrin-targeting agent with a unique mechanism of action, and provides a template for the development of integrin-targeting therapeutics.
Integrins are heterodimeric (combinations of different α and β subunits) cell surface receptors. These molecules not only play critical role for the cell adhesion to extracellular matrix (ECM) but also function as an inside-out and outside-in bidirectional signalling molecules to allow cell response to many biological cues. Abnormal expression of different pairs of integrins often associate with development and progression of various pathological conditions. Due to unique expression patterns and functionality of integrin αvβ3, in angiogenic endothelial cells, activated macrophages, metastatic cancer cells and matured bone-resorbing osteoclast cells, this pair of integrins has been intensively studied as a potential target for development of anti-angiogenic and anti-inflammatory drugs. Studies yield a number of successful examples. Among them are various antibodies against this integrin and most recently, Cilengitide, a Arg-Gly-Asp (RGD)-based peptidomimetic.

Nevertheless, most of the current approaches in development of therapeutic agents targeting integrin focus on ligand binding by using antibodies, cyclic peptides, disintegrin, peptidomimetics and small-molecule antagonists. A major drawback of targeting ligand binding of integrin is the activation of integrin signalling by the developed agent, which largely limit the clinical success of the integrin ligand-based antagonist/agonist. There is an urgent need to develop agents that target integrin at sites other than ligand-binding site. We report here the development of a new class of therapeutic protein agent by rational protein design. The designed protein targets integrin αvβ3 at a novel site, and triggers apoptosis of integrin αvβ3-expressing cells via recruitment and activation of caspase 8 to the cytoplasmic domain of integrin β3. In vitro and in vivo experiments demonstrate that the designed protein is very effective as an anti-angiogenic agent, providing a confirmation for the specific targeting of integrin αvβ3 by the designed protein agent.

Results
Designing a protein agent binds to a novel site of integrin αvβ3.

We employed an approach of in silico and in situ analysis to search for proteins that potentially bind to integrin αvβ3 at a site other than ligand binding site. We earlier observed a very weak affinity of domain 1 of both human and rat CD2 (referred to as D1-CD2), the proteins that were well studied in our laboratories, to the integrin αvβ3. Thus, we particularly attempted to dock D1-CD2 to various sites of integrin αvβ3. Because of the functional importance of βA domain of β3 in ligand binding and integrin signalling, we focused our attention on the βA domain. To validate our docking method, we first docked a physiologic ligand of integrin β3, the tenth type III RGD domain of wild-type fibronectin to integrin αvβ3. The RGD domain docking completely matched the crystal structure of the complex by Van Agthoven et al. (Supplementary Fig. 1a), indicating our docking method is appropriate. With the validation of our docking method, we carried out a randomized docking to the exposed surfaces of βA domain, D1-CD2 docked to a novel site, a groove in βA domain of β3 formed by the ’x2 helix’, ’B-C loop’ and ’a2—a3 loop’ (referred to as βA-groove), with various different orientations (Fig. 1a, Supplementary Fig. 1b). However, due to lack of strong contacts with residues of the βA-groove, the docking did not provide a favourable energy. To improve the docking, we made several mutations on D1-CD2 residues that may form important interactions with βA domain. Additional mutations were also introduced to counter potential structure disturbance and to maintain stable β-sheet packing. As expected, the docking-energies of these D1-CD2 variants on the βA-groove were substantially decreased (Fig. 1b). To verify the docking of D1-CD2 variants to integrin αvβ3, we re-performed the docking of variant 3 with another available crystal structure of integrin αvβ3 (4MMZ). The variant was docked to the same site of βA-groove. Due to structure difference between 1L5G and 4MMZ, the variant twisted about 10–15 degree in orientation in docking to 4MMZ (Supplementary Fig. 1c).

To test the results of computational modelling/docking, the rationally designed D1-CD2 variants were expressed in bacterial Escherichia coli and subsequently purified. Due to solubility, stability and other parameters, we chose one variant (variant 3 in Fig. 1b, which we call ProAgio) to carry out extensive characterizations. ProAgio exhibited structural properties very similar to that of the parental protein as demonstrated by the H-NMR (Supplementary Fig. 1d), far ultraviolet CD, and fluorescence spectra analyses, indicating that the engineered protein was well folded. We carried out binding analyses to determine the binding affinity and stoichiometry of ProAgio and integrin αvβ3 interaction. We first performed ELISA-based binding assays. Scatchard plot of the binding data indicated that the ProAgio and integrin αvβ3 binding could not fit into a one-to-one binding mode (Fig. 1c). However, in the presence of 3 mM of polyLys, the ProAgio and integrin αvβ3 binding fitted well into a one-to-one binding mode with a deduced dissociation constant (Kd) of 4.3 nM (Fig. 1c,d). To verify the ELISA-based binding analyses, we also carried out surface plasmon resonance (SPR)-binding studies. To avoid the problem of non-specific interactions, SPR binding experiments were carried out using PEGylated ProAgio (30 kDa PEG chain). PEGylated ProAgio bound to integrin αvβ3 via an one-to-one binding mode with an affinity of deduced Kd 2 nM (Supplementary Fig. 1a and Fig. 1d), consistent with the ELISA-based binding analyses. The ProAgio and integrin interaction was metal ion (Ca2+) dependent, as addition of EGTA abrogated the interaction, indicating that maintenance of local structure of the βA domain is critical for the interaction.

To further verify the ProAgio and integrin αvβ3 interaction, we carried out cell attachment assays using culture plate coated with ProAgio. HUVEC cells have very high levels of αvβ3 expression (Supplementary Fig. 2a). The cells attached strongly to the ProAgio-coated plates (Fig. 1e). CHO and COS-7 cells do not express αvβ3 (refs 24,25). The cells did not attach to the plates. We then exogenously expressed αvβ3 in CHO and COS-7 cells (Supplementary Fig. 2b) and performed the same attachment analyses. Evidently, the αvβ3-expressing CHO and COS-7 cells attached strongly to the ProAgio-coated plates (Fig. 1f). As a control, CHO and COS-7 cells expressing integrin αvβ3 did not attach to the plate (Fig. 1g). Integrin αv can authentically pair with β3, β5 and βκ. To further test the specificity of ProAgio–integrin interaction, we carried out attachment assays with COS-7 cells expressing integrin αvβ3, αvβ5 and αvβκ (Supplementary Fig. 2c). Clearly, only the cells expressing αvβ3 attached strongly to the plate, while αvβ5- and αvβκ-expressing cells exhibited a weak attachment (over threefold less than that of αvβ3-expressing cells). The αvβκ-expressing cells almost did not attach to the plate (Supplementary Fig. 2d). The attachment assays suggested that ProAgio interacted with integrin αvβ3 on the cell surface. Interaction of ProAgio with the integrin was further verified by co-immunoprecipitation of ProAgio with integrin β3 in HUVEC cell extracts (Supplementary Fig. 2e).
Figure 1 | Design of protein agent ProAgio binds to integrin α3β3 at a novel site (a) Docking of D1-CD2 to βA domain of integrin β3 as in a. The (ΔE) is the difference of docking energy between D1-CD2 and a variant calculated by the docking programme. (b) Docking of D1-CD2 and three variants (mutations indicated) to βA domain of integrin β3 as in b. The (ΔE) is the difference of docking energy between D1-CD2 and a variant calculated by the docking programme. (c) The representative scatter plots of binding data of binding of ProAgio to integrins α3β3 in the presence of 3 mM polylysine (Left) and absence of polylysine (Right). The dots are binding data. Solid line in left is fitting line. The fitting line clearly indicates n=1 for one-to-one binding. (d) The deduced dissociation (Kd) constants of ProAgio to integrins α3β3, αvβ3, and αvβ1 from the ELISA and SPR binding analyses. The n.d means the Kd could not be or were not determined. (e,f) Attachment of indicated cells to culture plate on which ProAgio (filled bars) or D1-CD2 (open bars) was coated was measured by counting the cells that attached to the plate after washing. (g) Attachment of CHO (open bars) or COS-7 (filled bars) cells with/without (control) expression of α3β3 or αvβ3 to culture plate on which ProAgio was coated was measured by the same cell counting as in (e) and (f). The control is CHO cells without integrin expression. The error bars in e, f, and g are s.d. from measurement of five independent experiments. NS P>0.05, ***P<0.001 calculated by unpaired two-tailed Student’s t-test. ND, not determined; NS, not significant.

We next analysed whether ProAgio indeed bound to the βA-groove. As predicted in our docking, ProAgio binding should not compete with RGD binding (they bind to different sites). We carried out an attachment assay, HUVEC cells were first incubated with Cilengitide, and subsequently assayed for the attachment to ProAgio in the presence of Cilengitide. Clearly, the presence of RGD did not prevent HUVEC cells from attaching to ProAgio, (Fig. 2a). Antibody LM609, a monoclonal antibody target at the ligand-binding site of integrin α3β3, is known to recognize the ligand binding site of integrin α3β3. Thus, we tested whether the presence of LM609 would block the ProAgio binding. Evidently, LM609 did not affect the interaction between ProAgio and integrin α3β3 (Fig. 2b). To further test whether ProAgio indeed binds to the βA-groove, we carried out chemical crosslinking of ProAgio with purified recombinant integrin α3β3 using Bis(Sulfosuccinimidyl)glutarate (BS2G, Supplementary Fig. 3a) as a crosslinker. Crosslinking followed by trypsin digestion and liquid chromatography-mass spectrometry (LC-MS) proteomic analyses indicated that ProAgio WEKTSKK (aa 35–43) was crosslinked to integrin α3 at the TEMKQER (aa 116–122; Fig. 2c, for details see online Supplementary Materials, and Supplementary Fig. 3b,e). We did not detect crosslinks of ProAgio with integrin β3 using BS2G as a crosslinker. It is possible that the bulky crosslinking reaction groups of BS2G prevented ProAgio from crosslinking to integrin β3. To further unambiguously determine the ProAgio-binding site, we
Figure 2 | ProAgio binds to integrin αvβ3 at the designed site. (a,b) Attachment of HUVEC cells to ProAgio coated plates. The attachment assays were carried out in the presence of 5 μM of Cilengitide or BSA as control (a), or 40 μg ml⁻¹ antibody LM609 or IgG as control (b). (c) The MS spectrum of peptide fragments resultant from trypsin digestion of crosslinks of ProAgio with integrin αvβ3 using BS2G as a crosslinker. The call-out is the enlarged region MS2 (indicated by the arrow) containing ProAgio–integrin crosslinking peak and analysed by MS/MS. The sequence on top is derived crosslinking a integrin sequence from MS/MS using pLink. (d) Docking model of ProAgio with integrin αvβ3 using Haddock 2.1 program by introducing the crosslinking restrains. The crosslinks are indicated by dotted lines. The mutation sites of the integrin αvβ3 are indicated in red. (e) Attachment of CHO cells with expression of integrin αvβ3 wild type or the mutant (β3-KKQ) to ProAgio/Vitronectin coated plates. The cell attachment to ProAgio are normalized to cell attachment to D1-CD2. (g) Immunoblot of integrin β3 or mutant (β3-KKQ) with ProAgio (IP:integrin β3) from the HUVEC cell lysate was examined by immunoblot (IB:ProAgio). The cells were treated with 5 μM ProAgio for 6 h before the extracts preparation. IB: IgG indicate the amounts antibody used in IP. Error bars in a–f are s.d. from measurement of five independent experiments. *P > 0.05, **P < 0.005 calculated by unpaired two-tailed Student’s t-test.

performed the crosslinking using another crosslinker glutaraldehyde (Supplementary Fig. 3a). Regions of NLKVII (aa 99–105) of ProAgio crosslinked to FNEEVKKQ (aa 203–210) of β3 by glutaraldehyde (Fig. 2d, for details see online Supplementary Materials, and Supplementary Fig. 3c). With the binding and crosslink results, we re-docked ProAgio to integrin αvβ3 with application of the crosslinking restrains using Haddock 2.1 (Fig. 2e). The modelling revealed several important contacts between ProAgio and the integrin. Guided by the modelling, mutations were introduced into β3 (for example, K233A and...
K234A). Computations showed that the mutations weakened the ProAgio and the integrin docking (the docking energy increased by 107 kcal per mole in the same docking model as shown in Fig. 2e). The mutations indeed reduced the attachment of the mutant expressing CHO cells (Supplementary Fig. 3d) to ProAgio (Fig. 2f), and abolished ProAgio and integrin β3 co-immunoprecipitation (Fig. 2g). Thus, we concluded from our binding, crosslinking and mutational studies that ProAgio interacted with integrin αvβ3 at the βA-groove.

To test whether ProAgio treatment would have effects on the integrin activity, we analysed the formation of actinfilament stress fibres and the focal adhesion complex in integrin αvβ3 expression HUVEC cells. Evidently, the actinfilament stress fibres decreased and eventually disappeared on the ProAgio treatment. The accumulation of vinculin at the tips of stress fibres were diminished on treatment (Fig. 3a), indicating disassociation of the focal adhesion complex. Furthermore, ProAgio treatment led to a rapid inactivation of FAK that was activated by attachment to ECM (Supplementary Fig. 4a). These results demonstrated that ProAgio abrogated the integrin functions in endothelial cells.

ProAgio activates caspase 8 at the cytoplasmic domain of integrin β3. Preceding tests suggested that a rationally designed protein that targets a unique site of integrin αvβ3 had been generated. We noted a strong effect of ProAgio in the induction of apoptosis of HUVEC cells while the cells were still attached in our previous assays. To our knowledge, this effect is different from that of other integrin-targeting agents. Thus, we assessed the effectiveness of ProAgio in the induction of cell apoptosis. ProAgio induced HUVEC cell apoptosis with EC50 around 1.4 μM (Supplementary Fig. 4b). We subsequently compared ProAgio side-by-side with several other agents that are known to have effects on HUVEC cells, such as Avastin, Endostar (an endostatin derivative approved for lung cancer treatment in China), LM609 and Cilengitide, using HUVEC cells. ProAgio was much more effective in inducing apoptosis than other agents (Fig. 3b). We further tested whether the effects of apoptosis induction were integrin αvβ3 dependent. To this end, cell apoptosis was analysed with several cell lines, HUVEC, PC-3, HEK and COS-7 with/without exogenous expression of integrin αvβ3, αvβ5 and αvβ6. HUVEC cells express high levels of αvβ3. PC-3 cells express marginal levels of the integrin25. HEK cells express αv but not β3 (ref. 27). COS-7 cells do not express αvβ3 (ref. 25). ProAgio did not induce apoptosis with COS-7 and HEK cells. The protein induced apoptosis of HUVEC and COS-7 cells with exogenous expression of αvβ3 integrin, and ProAgio did not induce apoptosis of αvβ3 and αvβ6-expressing COS-7 cells (Fig. 3c,d and Supplementary Fig. 4c). Moderate apoptosis was observed when PC-3 cells were treated with high concentration of ProAgio (>30 μM). The observations indicated that the effects of ProAgio in apoptosis induction were αvβ3 dependent.

An intriguing question is how ProAgio induces endothelial cell apoptosis by binding to the βA-groove of the integrin β3. We noted in preceding apoptosis tests that, in contrast to the effects of Cilengitide and other integrin-targeting molecules, ProAgio treatment did not lead to HUVEC cell floating/detaching (Fig. 4a), indicating that ProAgio induced apoptosis by a mechanism that is different from anoikis. To understand the molecular mechanism by which ProAgio induces endothelial cell apoptosis, we analysed the activation of various caspases in HUVEC cells on ProAgio treatment. Caspase 8, caspase 9, caspase 3 and caspase 7 were strongly activated (Fig. 4b). We then tested whether the apoptosis induction by ProAgio was dependent on activation of an initiation caspase, for example, caspase 8 and/or caspase 9 using caspase 8 and caspase 9 inhibitors. Caspase 9 was also inhibited.

Figure 3 | ProAgio induces apoptosis via targeting integrin αvβ3. (a) Representative confocal microscopic images of HUVEC cells stained by Rhodamine phallolidin (red), antibody against vinculin (green) and DAPI (blue). The cells were treated by the indicated protein agents for indicated times. (b-d) Apoptosis of various different cells ((b) HUVEC, (c) indicated cells and (d) COS-7 with αvβ3) or without (Control) integrin αvβ3 expression) was measured by cell counting 24 h after treatment with indicated agents. Cell apoptosis is presented as % apoptosis by defining the apoptosis of untreated cells as 0%. In all treatments, 5 μM (final concentration) of all agents were used except in one case in b wherein 50 μM Cilengitide was used (indicated). Error bars in b,c and d are s.d. from measurement of five independent experiments. NS P>0.05, **P<0.005, ***P<0.001 calculated by unpaired two-tailed Student’s t-test. Scale bar in a is 10 μm. NS, not significant.
inhibitor did not abolish the effects of ProAgio on apoptosis induction, while caspase 8 inhibitor largely abolished the effects (Fig. 4c). On the other hand, caspase 9 inhibitor did not abrogate the activation of caspase 8, while the activation of caspase 9 was largely inhibited by caspase 8 inhibitor (Fig. 4d), suggesting that the caspase 8 activation mediated the effects of ProAgio. It was observed by Stupack et al. that unligated integrin β3 can trigger cell apoptosis by directly recruiting caspase 8 to its cytoplasmic domain by a mechanism of so-called integrin-mediated death (IMD). Thus, we reasoned whether ProAgio binding to the βA-groove could trigger/enhance a mechanism that is similar to that of IMD. We examined whether ProAgio treatment led to direct recruitment and activation of caspase 8 to the cytoplasmic domain of integrin β3 by co-immunoprecipitation. Clearly, caspase 8 was co-immunoprecipitated with integrin β3 on ProAgio treatment (Fig. 4e). Caspase 9 did not co-immunoprecipitate with integrin β3 on the ProAgio treatment (Fig. 4e). As a comparison, Cilengitide did not result in strong recruiting caspase 8 to β3 under the same conditions (Fig. 4e). The results suggest that ProAgio may induce endothelial cell apoptosis by a mechanism that is similar to that of IMD and is very different from that of other integrin antagonists.

ProAgio effectively inhibits tumour growth and reduces tumour blood vessels. We next asked whether the integrin αvβ3-targeting ProAgio would be effective in the in vivo experiments. We chose to test the effectiveness of ProAgio on inhibition of angiogenesis. We first examined the anti-angiogenesis activity of ProAgio by the in vitro endothelial tube formation assay using HUVEC cells. Evidently, ProAgio almost completely disrupted the endothelial tube (Fig. 5a). To facilitate the in vivo test, ProAgio was site specifically PEGylated using PEG-20 kDa, a molecule with linear-shaped PEG chain (denoted as ProAgio-PEG), at an introduced Cys residue (Supplementary Fig. 5b). We further tested the effects of ProAgio inhibition of angiogenesis. We first examined the anti-angiogenesis activity of ProAgio by the in vitro endothelial tube formation assay using HUVEC cells. Evidently, ProAgio almost completely disrupted the endothelial tube (Fig. 5a). To facilitate the in vivo test, ProAgio was site specifically PEGylated using PEG-20 kDa, a molecule with linear-shaped PEG chain (denoted as ProAgio-PEG), at an introduced Cys residue (Supplementary Fig. 5b). We further tested the effects of ProAgio inhibition of angiogenesis by Matrigel plug assays. Evidently, ProAgio inhibited angiogenesis in the Matrigel plug assay. The activity was stronger than that of Avastin (Supplementary Fig. 5b). We further tested the effects of ProAgio inhibition of tumour growth in animal models of cancers. We generated xenograft model of PC-3 cells. Tumour-bearing mice were intraperitoneally administered various doses of ProAgio-PEG and PEGylated host protein, and buffer saline for 20 days via one dose every other day. The treatments started at the fifth day post tumour inoculation. It was clear that ProAgio-PEG inhibited the tumour growth almost completely at the dose of 10 and 20 mg kg⁻¹ (two and one tumours completely disappeared in the 20 and 10 mg kg⁻¹ dose groups, respectively). As controls, the tumours grew at normal rate in mice treated with buffer and the PEGylated host proteins. The effects of ProAgio-PEG on tumour growth inhibition showed a clear dose

Figure 4 | ProAgio recruits and activates caspase 8 at cytoplasmic domain of integrin β3. (a) Representative phase contrast microscopic images of endothelial HUVEC cells that were treated by indicated agents for 8 h. (b) Levels of indicated cleaved caspases (C-caspases) in HUVEC cell lysates were analysed by immunoblot using antibodies against various cleaved caspases. The cells were treated by 5 μM ProAgio for 10 h. (c) Apoptosis of HUVEC cells that were treated by 5 μM ProAgio in the presence of caspase 8/9 inhibitors was analysed by apoptosis kit. Apoptosis was presented as % Apoptosis by defining the cells that were untreated as 0%. Error bars are standard deviations from measurement of five independent experiments. (d) Levels of cleaved caspases 8/9 (C-caspase 8/9) in HUVEC cell lysates were analysed by immunoblot using antibody against cleaved caspase 8/9. The cells were treated by 5 μM ProAgio and caspase 8/9 inhibitor for 5 h. (e) Co-immunoprecipitations of caspase 8 (Upper) and caspase 9 (Bottom) with integrin β3 (IP:integrin β3) were analysed by immunoblots (IB:caspase 8/9). The cells were treated by the indicated agents 5 h before the preparation of extracts. Immunoblot of integrin β3 (IB:integrin β3) indicates amount of β3 was precipitated down in the co-IPs. Immunoblot of GAPDH (IB:GAPDH) in b and d are loading controls. ***P<0.001 calculated by unpaired two-tailed student t-test. Scale bar in a is 200 μm.
dependency. However, the dose dependence became less significant after 10 mg kg\(^{-1}\) (Fig. 5b,c). ProAgio-PEG was also effective when administered at a later time of tumour growth (Fig. 5d,e, two tumours shrunken in size). To analyse the effects of the treatment on tumour vessels, we carried out immunostaining of CD31, an endothelial marker, with the tissue sections prepared from collected tumours. Immunostaining demonstrated that the blood vessels were markedly reduced (Fig. 5f). Quantitative analyses of the CD31 staining indicated that there were marked reductions in vessel density, branch points and vessel lengths (Fig. 5g). To further assess the effectiveness, we carried out experiments to compare side-by-side the effect of ProAgio-PEG versus Avastin and ProAgio-PEG versus Endostar using the PC-3 xenografts. ProAgio-PEG was significantly more effective in the inhibition of tumour growth compared with those of the Avastin and Endostar treatments.

**Figure 5 | ProAgio effectively inhibits tumour growth and disrupts tumour vessels.** (a) Representative phase contrast microscopic images of endothelial tubes of HUVEC cells under treatment of indicated agents (5 μM). (b–e) Growth of xenograft PC-3 tumours under the treatment of indicated agents was monitored by; (b,d) growth curve by measuring tumour volumes every four days, or (c,e) endpoint weights of the harvested tumours. Treatments started 5 days (b)/(c) or 17 days when tumours reached average of 250 mm\(^3\) in size (d)/(e) post tumour inoculations. (f) Representative images of immunofluorescence staining of tissue sections prepared from the harvested tumours with antibodies against mouse CD31 (Green). The blues are DAPI stains. (g) Quantitative analyses of vessel lengths, densities, and branch points (manually counting) of the CD31 staining of the tumour tissue sections. The vessel density and number of branch points are counted in 319.8 × 319.8 μm\(^2\) view field using imaging-J. The quantization was average values of randomly selected three fields in position matched 4 sections from each tumour. Error bars in b,c,d and e are s.d. from measurement of experimental six mice. NS P > 0.05, **P < 0.005, ***P < 0.001 calculated by unpaired two-tailed Student’s t-test. Scale bar in a is 200 μm in f is 20 μm. NS, not significant.
ProAgio is not toxic to mouse tissues and organs. A specific integrin α₃β₁-targeting agent should be less/nontoxic to existing blood vessels in normal tissue/organs. To assess whether ProAgio disrupted the non-tumour blood vessels, we prepared tissue sections from liver, lung, heart, spleen and kidney of the mice that were treated with different agents. The tissue sections were analysed by Hematoxylin staining and CD31 immunostaining. Hematoxylin staining revealed that there was no obvious abnormality in tissue anatomy structure, and no damage lesion/necrosis was observed (Supplementary Fig. 7a). Immunofluorescence staining using the anti-CD31 antibody suggested that there was no disruption or reduction of blood vessels in the liver, lung, heart and kidney on the treatments with ProAgio-PEG compared with those in the groups that were treated with the PEGylated D1-CD2 and buffer saline (Supplementary Fig. 7a). The treatments did not lead to any abnormal weight gain or loss (Supplementary Fig. 7b). To further analyse the toxicity of ProAgio, healthy CD-1 mice were intravenously administered three doses of 60 mg kg⁻¹ of ProAgio-PEG in 48 h and observed for 24 days. All animals behaved normally. Blood and urine samples were collected. Examination of plasma AST, ALP, TnT, creatinine and urine albumin 48 h after the agent’s administrations indicated that ProAgio-PEG at the dose did not cause damage to animal’s liver, kidney and heart (Supplementary Fig. 7c).

Discussion

We have successfully developed a protein agent targeting integrin α₃β₁ at a novel site by rational protein design. In vitro and in vivo experiments demonstrate the effectiveness of our designed protein. The developed agent is not toxic to non-cancerous blood vessels and other tissue/organs, providing an excellent candidate for future potential clinical development. The βA-groove is present in almost all other β-integrin. Thus, our approach may be applicable to develop agents targeting the similar βA-groove of other integrin pairs.

Due to unique expression patterns and frequent disease association, several pairs of integrin are promising targets for the development of therapeutics for a number of pathological conditions. Most approaches focus on the integrin ligand binding. However, significant drawbacks, such as the effect of activation of integrin signalling by ligand binding limit the clinical success of the integrin ligand antagonist. Most recently, Van Agthoven et al. reported a novel interaction of a variant of physiologic ligand fibronectin with integrin β₃. The interaction did not lead to conformation changes resulting from ligand binding, thus consequentially activating integrin outside-in signalling, which provides a novel concept for developing integrin ligand-based antagonist. Our approach does not target ligand binding (Fig. 6b). In fact, ProAgio induced HUVEC apoptosis with or without ligand binding, and ProAgio binding did not interfere with RGD binding (Figs 6a and 2a), suggesting that the effects of ProAgio are independent of ligand binding. Effective induction of cell apoptosis through integrin α₃β₁ via a mechanism different from anoikis is a unique feature of ProAgio. This feature may bring a very important advantage in future potential clinical applications, as ProAgio does not need to compete with strong integrin–ligand interactions, and does not need to induce anoikis that may not occur in actual situations due to the fact that the cell-to-ECM adhesions always involve interactions between multiple pairs of integrin and multiple types of ECM. It is intriguing that ProAgio binding triggers recruiting and activating caspase 8 at cytoplasmic domain of β₃, a mechanism of apoptosis induction similar to that was observed by Stupack et al. It is speculated that IMD would occur during tissue remodelling to remove excess unwanted cells. Our study further suggests that this apoptosis mechanism can actually be induced by a molecular interaction involved in the allosteric β₂ domain of β₃ integrin. This is important as the notion provides a novel concept to develop integrin α₃β₁ target therapies that would be able to directly remove disease causative and integrin α₃β₁-expressing cells regardless of ligated or unligated integrin. Integrin β₃ knock-out allow developing larger tumour with more vessels. Since the activity of ProAgio is dependent on the presence of high levels of integrin α₃β₁, therefore, it would be expected that ProAgio will not be effective in integrin β₁ knock-out mouse.

The βA-groove is very close to the RGD-binding site in the βA domain. An open question is how the ProAgio–integrin interaction at the groove triggers effects that are so different from those of RGD binding. One plausible speculation is that ProAgio-binding to the βA-groove induces conformation changes that are different from that of RGD ligand binding, which consequently trigger different signalling that allows caspase 8 recruiting to the cytoplasmic domain of β₃. Indeed, previous structural study of the integrin–RGD complex showed that RGD interacts with a site formed by ‘D3-A3’ and ‘D4-A4’ loops of β₃-propeller domain of α₃. The Aspartate of RGD interacts with BA domain of β₃ integrin, where the carbohydrate side chain of the Asp protrudes into a cleft formed by βA ‘A-α₂’ and ‘C-α₃’ loops. These interactions are critical for an inward conformational change of the βA domain and the consequential integrin signalling. However, our modelling, crosslinking and mutations demonstrate that ProAgio does not contact these RGD interacting elements. Instead, ProAgio contacts α₂ helix, ‘B-C’ loop and ‘A-α₂’ loop (Figs 2e and 6b), which are not involved in RGD binding. An ultimate answer to the question may require a comprehensive structural study to understand the differences in structure/conformation changes on ProAgio binding and RGD ligand binding.

In our modelling, ProAgio only contacts β₁. It is intriguing why ProAgio has a specificity for α₃β₁. Careful examination of X-ray crystal structures of α₃β₁ and 2ιιbβ₃, the other authentic α subunit that paired with β₃, reveals that the ProAgio-binding site, the β-groove, is different in both cases (Supplementary Fig. 8). The key contact residues K, K and Q locate in a region of α2′ helix in α₃β₁, while the same region forms a loop in 2ιιbβ₃. The relative orientation of α2 and α2 helices are important for the ProAgio binding (from our docking and modelling), while these two helices are pushed far apart in 2ιιbβ₃ (Supplementary Fig. 8). Thus, ProAgio can only binds to α₃β₁, but not 2ιιbβ₃, as shown in our binding and cell attachment studies. Apparently, the fact that ProAgio interacts with α₃β₁ but not 2ιιbβ₃ provides another support for the ProAgio and α₃β₁ interaction site. Interestingly,
COS-7 cells expressing β3 (without αv) were able to attach to ProAgio. ProAgio was also able to less effectively induce apoptosis of the β3-expressing COS-7 cells (Fig. 6c–e). These results provide an additional support for our design that ProAgio mainly contacts with β3.

Methods

Reagents, antibodies, cell lines and protein expression/purification. Cell lines PC-3, 4T-1, CHO, HEK293 and COS-7 were purchased from ATCC, and HUVEC cells were purchased from Invitrogen. The cells were cultured by following the vendor’s instructions. Caspase 8 Inhibitor II, Caspase 9 Inhibitor III, Cilengitide, Caspase 8 Inhibitor II, Caspase 9 Inhibitor III, Cilengitide, Avastin was a prescription drug purchased from Walgreens. Antibodies Endostar was purchased from SIMCERE China. PEGylation agent Maleimide-20K Aldrich, respectively. Avastin was a prescription drug purchased from Walgreens.

Figure 6 | ProAgio and integrin αvβ3 interaction is independent of RGD binding. (a) Apoptosis of HUVEC cells was measured by cell counting 24 h after treatment with 5 µM of ProAgio. The cells were incubated with 5 µM Cilengitide (filled bar) or buffer (open bar) before the ProAgio treatment. Cell apoptosis is presented as % apoptosis by defining the apoptosis of untreated cells as reference 0%. (b) Cell attachment of COS-7 cells to culture plate coated with ProAgio. The cell attachments are presented as total number of cells attached to the plate per view field (average of three fields). (c) Apoptosis of COS-7 cells with expression of αvβ3 (COS7αvβ3) or β3 (COS7β3) treated by 5 µM ProAgio. Cell apoptosis is presented as % apoptosis by defining the apoptosis of untreated cells as reference 0%. Error bars in a, d and e are s.d. from measurement of five independent experiments. NS P > 0.05, ** P < 0.005, *** P < 0.001 calculated by unpaired two-tailed Student’s t-test. NS, not significant.

The docking was performed with HADDOCK 1.2, supporting docking to make use of experimental information to drive the docking while allowing for various degrees of flexibility21. D1-CD2 was first randomly docked into βα domain of β3. For comparison, three different variants were also randomly docked into βα domain of β3. To further refine the binding of integrin and ProAgio, ProAgio (variant 3) was docked into integrins αvβ3 together with our crosslinking-drive refinements. The active residues used to define the ambiguous interaction restraints (AIRs) were those showing the direct crosslinking contacts and were solvent accessible. The surface accessibility data were calculated with the program NACCESS. Only the residues having either backbone or side-chain relative solvent accessibility above 40% were retained for the definition of active and passive residues. The passive residues correspond to the residues that are surface neighbours of the active residues as identified by visual inspection and that have a high level of solvent accessibility (40%). A total of 1,000 conformers of the integrin with ProAgio or D1–CD2 complex were generated using only AIRs, van der Waals energy and electrostatic terms in crystallography and NMR System (CNS). The 200 conformers with lowest molecular energies were subsequently subjected to semi-flexible simulated annealing and refinement with explicit water and only backbone restraints for residues outside the interface. The solutions were clustered using an arbitrary root-mean-square deviation (RMSD) and ranked according to their intermolecular interaction energy (sum of Van der Waals, Eelec electrostatic, Evdw and AIRs energy terms, EAIR). The lowest energy structures of each cluster were selected for the analysis.

ELISA binding. The commercial recombinant integrins αvβ1, αvβ3, and β3 were immobilized on ELISA plates. Various concentration of ProAgio were added into the plates. In some cases, polyLys was co-added into the plates at a final concentration of 3 mM. After incubation and extensive washing, antibody that recognize ProAgio was added into mixture. The plates were incubated at room temperature for 4 h. Excessive antibody was removed by washing. The bound ProAgio was quantified by secondary antibody that recognizes anti-ProAgio antibody. The binding data were plotted and analysed via Scatchard analyses to deduce the Kd and binding stoichiometry. SPR. The commercial recombinant integrins αvβ1, αvβ3, and β3 were diluted to a concentration of 100 µg ml−1 and immobilized on the CM5 chip with response units around 500. Then PEGylated ProAgio bindings were carried out at various concentrations with the running buffer of 1× HBSS 10 mM HEPES, 150 mM NaCl, 5 mM MgCl2, pH 7.4. The flow rate of 50 µl min−1, and the binding time was 12 min. Kds were deduced by calculation via binding curves of various concentrations.
Nude mice xenograft and treatments, and toxicity. All animal experiments were carried out in accordance with the guidelines of Institutional Animal Care and Use Committee (IACUC) of Georgia State University. Six-week-old male/female nude mice or Balb/c mice were subcutaneously injected with $5 \times 10^6$ of PC-3 or 4 T1 cells. Tumour formation and volumes were assessed every 2-4 days. Tumour volumes were measured by two perpendicular diameters of the tumours with the formula $\frac{1}{2} \times (\text{length}) \times (\text{width})^2$. The tumours were then subjected to intraperitoneal injections of appropriate agents at indicated frequencies. The treatments started 5 days post tumour inoculations or till tumour reached the average size of 230 mm$^3$. The tumours were collected and weighed at the end of the experiments. Tissue sections were prepared from cancer and tumour or other organs. For toxicity studies, 6-week-old male healthy, male healthy CD-1 mice were intravenously injected with appropriate agents at indicated frequencies and doses. The animals were returned to their cages after injection. The behaviours of animals were closely monitored. Blood samples were collected at appropriate time points. For analyses of urine albumin, animals were placed in metabolic cages. Urine samples were collected in 24 h. At the end of experiment, animals were euthanized by CO$\textsubscript{2}$ narcosis. Tissue samples were collected for further analyses. The sections were subjected to immunofluorescence microscopy.

Apoprotosis. For determination of EC$\textsubscript{50}$ of ProAgio and the effects of caspase 8/9 inhibitors, HUVEC cells were cultured overnight. The cells were shifted to fresh medium next morning. Various concentrations of ProAgio or D1-C2D2, or caspase 8/9 inhibitors with 5 μM ProAgio were added into culture medium. After 24 h incubation, caspase 9 apoptosis was determined using an apoptosis kit. For all other apoptosis measurements, appropriate cells were cultured overnight. The cells were shifted to fresh medium next morning. Appropriate agents were added into the medium to appropriate concentrations. After 24 h incubation, the cell apoptosis was determined by cell counting using untreated cells as a reference. The cell counting was repeated five times in each experiment.

Immunofluorescence staining. HUVEC cells were grown on glass coverslips coated with fibronectin for immunofluorescence microscopy. After treatment with proteins, cells were fixed with cold (-4 °C) 4% PFA in PBS (U5) for 15 min and blocked by incubating with 3% BSA/PBS at 37 °C for 1 h. Vinculin antibody (1:100) was added and incubated overnight at 4 °C. The cells were washed with PBS for 10 min at room temperature before incubating with a 1:500 dilution of Alexa-488 conjugated secondary antibody. The cells were incubated with Phalloidin conjugated rhodamine for 30 min at 37 °C. Cells were mounted with Prolong-Gold antifade reagent that contained DAPI (Invitrogen, Carlsbad). For immunofluorescence staining of tissue sections, snap frozen tissue blocks were sliced into 10 μm thick sections using a cryostat. The procedure similar to that used in immunostaining of fixed cells was used for tissue section immunofluorescence staining.

Vessel quantification. Sections from tumours or various organs of mice that were treated by appropriate agents were stained using an anti-mouse CD31 antibody and a green fluorescence-conjugated secondary antibody. After the highest vessel density within a section was determined under lower objective lens (×5), an area of 319.8 × 319.8 μm$^2$ with the highest amount of vessels was scanned under a ×20 objective lens and ×10 ocular lens. The CD31 immunofluorescence staining was quantified by manual counting using Imaging-J. Vessel Length is the total number of vessel length within each of the image was measured using a Zeiss LSM image browser. Mean Vessel Density was determined using methods described by Weidner et al. Briefly, any clear pattern of fluorescent stained or a cluster within the tumour tissue that separated from connective tissues was counted as one vessel. Microvessels in sciatric area or adjacent to connective tissues were not considered. Branch points was determined by manually counting the number of branch points under the microscopic view. Any junction of two lines of CD31 stains counts as one branch point. All data were shown in 319.8 × 319.8 μm$^2$ area of view field and are the average of repeating three view fields per section. Four sections from each tumour/organ were counted.

Statistical calculations. Data were statistically analysed by comparing two appropriate groups. The P values were calculated using unpaired two-tailed Student’s t-test. In all figures and tables, NS means $P>0.05$ and statistically insignificant, *P<0.05, **P<0.01, and ***P<0.001.

References

Acknowledgements
We thank Drs Lianqwei Li, Vaishali Pannu and Mr Yinwei Zhang for their critical comments. We are grateful to Ms. Birgit Neunhau for her assistance in microscopic imaging. This work is supported in part by research grants from National Institute of Health (CA175112, CA118113) and Georgia Cancer Coalition to Z.-R.L. Researches in Dr Jenny Yang’s laboratory is supported by National Institute of Health (EB007268, HL042220), in Grossniklaus’s laboratory is supported by National Institute of Health (EY06306) and Research to Prevent Blindness, Inc. (New York, NY), and in Dr Ivaylo Ivanov’s laboratory is supported by National Science Foundation (NSF, CAREER 1149521 and National Institutes of Health grant (GM110387)). R.C.T. is supported by a MBD fellowship, GSU.

Author contributions
Z.-R.L. conceptualized, planned and coordinated the study. Z.-R.L. wrote the paper. R.C.T. and L.Y. conducted most of experiments, data analyses and participated in paper writing. H.Y. participated in the computation modelling and D1-CD2 mutant designing, participated in data analyses and paper writing. Hsiauwei Lee participated in the D1-CD2 mutant design. I.I. and C.Y. carried out the docking analyses. H.Y. and H.E.G. performed part of IF and H&E staining and histology analyses. S.W. and C.M performed MS experiments and MS data analyses. L.S helped in protein expression and purification. All authors discussed the results and commented on the paper.

Additional information
Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: Z.-R.L. holds shares in the company ProDa BioTech LLC, which licensed the rights to commercialize ProAgio. L.S. holds shares in the company Amoytop Biotech Co. Ltd, which licensed the rights to commercialize ProAgio. R.C.T. is supported by a MBD fellowship, GSU. 

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Turaga, R. C. et al. Rational design of a protein that binds integrin avb3 outside the ligand binding site. Nat. Commun. 7:11675 doi: 10.1038/ncomms11675 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material.

To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/